Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
Under the terms of the agreement, Arrakis will lead research activities for the identification of RNA-targeted small molecule (rSM) binders against a broad set of targets nominated by Amgen
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
The event is expected to attract more than 100 senior professionals from pharmaceutical companies, CROs, regulatory agencies, and technology organisations
Mumbai event on June 24–25 will spotlight real-world impact of pharmacovigilance beyond AI adoption
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
